Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
GT Medical Technologies
GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
June 9, 2026
ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
May 30, 2026
GT Medical Technologies Announces First Patients Treated with GammaTile in the BRIDGES Trial for Newly Diagnosed Glioblastoma
January 14, 2026
GT Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
December 30, 2025
GT Medical Technologies Welcomes New GammaTile® Center of Excellence Program Designation
December 19, 2025